China Health Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

China Health Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

1.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 05

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

Sep 11

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

Sep 23

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Sep 02

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

Feb 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 673 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 673 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

China Health Group Piyasaya Karşı Temettü Getirisi

673 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (673)	n/a
Pazarın Alt %25'i (HK)	3.3%
Pazarın En İyi %25'i (HK)	8.1%
Sektör Ortalaması (Healthcare)	4.1%
Analist tahmini (673) (3 yıla kadar)	n/a

Önemli Temettü: 673 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 673 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 673 şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 673 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

China Health Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

China Health Group Limited to Report First Half, 2025 Results on Nov 29, 2024

New minor risk - Share price stability

New minor risk - Share price stability

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Non-Executive Director recently bought HK$291k worth of stock

China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director

Full year 2024 earnings released: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited, Annual General Meeting, Sep 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: HK$0.084 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited to Report Fiscal Year 2024 Results on Jun 27, 2024

First half 2024 earnings released: HK$0.032 loss per share (vs HK$0.066 loss in 1H 2023)

New major risk - Revenue and earnings growth

China Health Group Limited to Report First Half, 2024 Results on Nov 30, 2023

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

New minor risk - Shareholder dilution

China Health Group Limited, Annual General Meeting, Sep 18, 2023

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

New minor risk - Insider selling

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

China Health Group Limited to Report Fiscal Year 2023 Results on Jun 30, 2023

Executive Chairman recently bought HK$932k worth of stock

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

China Health Group Limited Provides Earning Guidance for the Six Months Ended 30 September 2022

China Health Group Limited to Report First Half, 2023 Results on Nov 30, 2022

Less than half of directors are independent

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

China Health Group Limited, Annual General Meeting, Sep 30, 2022

Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021)

Full year 2022 earnings released

China Health Group Limited to Report Fiscal Year 2022 Results on Jun 30, 2022

China Health Group Limited announced that it expects to receive HKD 82 million in funding

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Full year 2021 earnings released: HK$0.002 loss per share (vs HK$0.009 loss in FY 2020)

No-Executive Director has left the company

China Health Group Limited Announces Board Changes

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

First half 2021 earnings released: HK$0.001 loss per share

First half 2021 earnings released: HK$0.001 loss per share

China Health Group Limited to Report First Half, 2021 Results on Nov 30, 2020

Full year earnings released - HK$0.0089 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin